Benvenuto nel sito web dedicato al melanoma!

Il melanoma maligno è il più pericoloso tra i tumori cutanei ed è una neoplasia che origina dai melanociti, cellule preposte alla produzione della melanina.

La lettura delle varie pagine del sito vi aiuterà a comprendere i vari aspetti del melanoma, mentre nella sezione “Risorse sul melanoma” troverete informazioni sui links, libri, congressi ed altre informazioni utili.

Termini di ricerca:

Questo post è disponibile anche in: Inglese

Dabrafenib and trametinib: a drug combinations to treat metastatic

Dr Georgina Long from Westmead Hospital and the Melanoma Institute Australia and colleagues report that combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in progression-free survival, response rate and duration of response in 162 patients with melanoma that had BRAF V600 mutations. Patients in the study received either dabrafenib 150mg twice daily;

Una nuova combinazione di farmaci si rivela promettente nel melanoma metastatico

Nella cura del melanoma metastatico si rivela promettente la terapia di associazione tra dabrafenib (un BRAF inibitore) e trametenib (MEK inibitore). Tale associazione rivela un allungamento della vita rispetto ai pazienti trattati con solo dabrafenib. I risultati sono stati presentati a ESMO 2012 Congress of the European Society for Medical Oncology a Vienna. Lo studio è in

The Unique Clinical Characteristics of Melanoma Diagnosed in Children

Studies have demonstrated a higher rate of nodal metastases in melanoma of childhood, but there is controversy about the overall prognosis relative to adults. We describe a large single-institution experience with pediatric melanoma and assess prognostic characteristics Retrospective review identified 126 patients diagnosed with melanoma at <21 years of age and referred for treatment from 1986 to

Il melanoma si manifesta differentemente in bambini e adulti

Studies have demonstrated a higher rate of nodal metastases in melanoma of childhood, but there is controversy about the overall prognosis relative to adults. We describe a large single-institution experience with pediatric melanoma and assess prognostic characteristics Retrospective review identified 126 patients diagnosed with melanoma at <21 years of age and referred for treatment from 1986 to

Il Viagra aumenta l’efficacia delle cellule anti-melanoma

Uno studio eseguito in Germania ha evidenziato che cavie geneticamente predisposte ad avere un melanoma a cui era somministrato Viagra con l’acqua, avevano una sopravvivenza due volte superiore alle cavie non trattate. Il farmaco agirebbe sul sistema immunitario rendendolo più efficace nel combattere il melanoma. Lo studio è stato eseguito da ricervìcatori del German Cancer

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved by the US Food and Drug Administration for the treatment of metastatic melanoma. We review the literature on managing the adverse effects and

Gestione degli eventi avversi immuni-correlati dopo terapia con ipilimumab

Un articolo pubblicato nel Journal of Clinical Oncology evidenzia la gestione degli effetti collaterali della terapia con ipilimumab e tremelimumab nel melanoma metastatico: “Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved

Elesclomol role in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood.  Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a

L’ Elesclomol blocca la fosforilazione nel melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood.  Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a